Gain Therapeutics (GANX) Competitors $1.81 -0.10 (-5.24%) Closing price 04:00 PM EasternExtended Trading$1.81 0.00 (0.00%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. RZLT, PHAT, PROK, TVGN, BTMD, GNFT, KOD, AMRN, MNPR, and SLDBShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Rezolute (RZLT), Phathom Pharmaceuticals (PHAT), ProKidney (PROK), Tevogen Bio (TVGN), biote (BTMD), Genfit (GNFT), Kodiak Sciences (KOD), Amarin (AMRN), Monopar Therapeutics (MNPR), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Rezolute Phathom Pharmaceuticals ProKidney Tevogen Bio biote Genfit Kodiak Sciences Amarin Monopar Therapeutics Solid Biosciences Rezolute (NASDAQ:RZLT) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership. Which has more risk & volatility, RZLT or GANX? Rezolute has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Which has preferable earnings & valuation, RZLT or GANX? Gain Therapeutics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRezoluteN/AN/A-$68.46M-$1.15-3.49Gain Therapeutics$50K1,070.00-$22.27M-$0.86-2.10 Do institutionals & insiders have more ownership in RZLT or GANX? 83.0% of Rezolute shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 18.4% of Rezolute shares are owned by insiders. Comparatively, 7.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor RZLT or GANX? In the previous week, Rezolute had 9 more articles in the media than Gain Therapeutics. MarketBeat recorded 19 mentions for Rezolute and 10 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.69 beat Rezolute's score of 0.67 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 5 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor RZLT or GANX? Rezolute received 35 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 80.43% of users gave Rezolute an outperform vote while only 73.58% of users gave Gain Therapeutics an outperform vote. CompanyUnderperformOutperformRezoluteOutperform Votes7480.43% Underperform Votes1819.57%Gain TherapeuticsOutperform Votes3973.58% Underperform Votes1426.42% Is RZLT or GANX more profitable? Rezolute's return on equity of -70.27% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RezoluteN/A -70.27% -62.41% Gain Therapeutics N/A -203.91%-128.05% Do analysts rate RZLT or GANX? Rezolute currently has a consensus price target of $12.14, indicating a potential upside of 202.81%. Gain Therapeutics has a consensus price target of $8.20, indicating a potential upside of 353.04%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Rezolute.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryRezolute beats Gain Therapeutics on 9 of the 16 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.50M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-1.658.9226.8419.71Price / Sales1,070.00250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book1.876.466.794.50Net Income-$22.27M$143.98M$3.23B$248.18M7 Day Performance-2.69%3.04%4.07%1.14%1 Month Performance4.02%7.44%12.52%15.20%1 Year Performance-27.60%-2.46%16.83%6.56% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics1.9908 of 5 stars$1.81-5.2%$8.20+353.0%-23.9%$53.50M$50,000.00-1.6520News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpRZLTRezolute2.6605 of 5 stars$3.73+0.8%$26.43+608.5%+40.6%$225.80MN/A-3.0640Analyst RevisionPHATPhathom Pharmaceuticals3.8864 of 5 stars$3.15+0.3%$17.60+458.7%-59.8%$219.91M$81.86M-0.55110Positive NewsGap DownHigh Trading VolumePROKProKidney1.844 of 5 stars$0.75+4.0%$5.00+566.7%-79.6%$219.52M$76,000.00-1.363TVGNTevogen Bio2.8837 of 5 stars$1.19+9.2%$7.10+496.6%+48.7%$218.83MN/A0.003BTMDbiote2.8264 of 5 stars$3.99-0.3%$8.00+100.5%-29.4%$218.29M$197.19M15.35194GNFTGenfit0.9712 of 5 stars$4.36+1.4%$13.00+198.2%+8.0%$217.98M$67.00M0.00120Gap UpKODKodiak Sciences3.6832 of 5 stars$4.13+9.5%$9.00+117.9%+24.5%$217.87MN/A-1.1390Earnings ReportAnalyst RevisionGap DownAMRNAmarin0.3455 of 5 stars$10.42+0.1%$7.00-32.8%-36.9%$215.79M$228.61M-115.78360MNPRMonopar Therapeutics2.9031 of 5 stars$35.10-11.0%$55.33+57.6%+1,090.5%$214.64MN/A-17.8210Gap DownSLDBSolid Biosciences4.2895 of 5 stars$2.90+5.1%$15.67+440.2%-67.7%$213.91M$8.09M-0.95100Earnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Rezolute Alternatives Phathom Pharmaceuticals Alternatives ProKidney Alternatives Tevogen Bio Alternatives biote Alternatives Genfit Alternatives Kodiak Sciences Alternatives Amarin Alternatives Monopar Therapeutics Alternatives Solid Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GANX Stock Free GANX Stock Alerts